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Validation of a dosing regimen for fixed-dose, weight-
adjusted, subcutaneous unfractionated heparin for the acute 
treatment of venous thrombo-embolism in a population 
from a resource-constrained environment
J I Munsamy, H Kertland, A Parrish
To the Editor: A study in Canada and New Zealand (Kearon 
et al.) suggested that fixed-dose unmonitored subcutaneous 
(SC) unfractionated heparin (UFH) is as effective and safe 
as low-molecular-weight heparin (LMWH) for the acute 
treatment of venous thrombo-embolism (VTE). While this 
trial has limitations, it provides evidence to support the use 
of SC UFH in a resource-constrained environment. However, 
because public sector patients with VTE in South Africa often 
have multiple co-morbidities and are thinner and younger than 
those in that study, the local validity of the published dosing 
regimen is unclear.
Background
VTE is a potentially fatal disorder manifesting as deep-vein 
thrombosis (DVT) and pulmonary embolism (PE).1 Initial 
standard management of VTE was with intravenous UFH 
with dose adjustments according to the partial thromboplastin 
time (PTT).2 This regimen is effective, but is limited by the 
requirements for intensive monitoring and ensuring a constant 
heparin infusion rate. The introduction of SC LMWH using 
weight-based dosing offered an attractive alternative to UFH, 
with proven efficacy and safety.3 Although LMWH is more 
expensive, this cost is offset by reduced laboratory costs, as 
PTT monitoring is not required.
Kearon et al. performed a randomised, open-label, 
adjudicator-blinded trial (FIDO) suggesting that fixed-dose, 
weight-adjusted SC UFH, without PTT monitoring, appeared 
as effective and safe as fixed-dosed, unmonitored SC LMWH in 
patients with acute VTE.4 SC UFH was given as a loading dose 
of 333 units/kg followed by 250 units/kg 12-hourly.4 A recent 
review concluded that SC UFH appeared to be as effective 
and safe with regard to rates of bleeding and death.5 However, 
the authors declared that more robust data were needed to 
recommend SC UFH without PTT monitoring.
Although the use of LWMH is established, the considerably 
less costly approach of fixed-dose, weight-adjusted, SC UFH 
is appealing in a resource-constrained setting. However, 
there appears to be no published evidence to indicate that 
this regimen has been validated locally in patients who differ 
from those in the FIDO study in age, weight, and presence of 
multiple co-morbidities.
Methods
The protocol was approved by the East London Hospital 
Complex Research and Ethics Committee. The sample size was 
based on a previous study that looked at optimal dosing of 
SC UFH for the treatment of DVT.6 Patients provided written 
informed consent. Concurrent chart review was performed 
on all consecutive eligible patients (age ≥18 years; newly 
diagnosed VTE) admitted between November 2008 and 
February 2009 to internal medicine wards at Cecilia Makiwane 
Hospital and who had been prescribed SC UFH according 
to the FIDO study. All other aspects of care were delivered 
as standard of care. The primary measure of interest was the 
proportion of patients with a therapeutic PTT (patient PTT  
1.5 - 2.5 times the control value) measured approximately 6 
hours after the morning dose of UFH on any day from the 
2nd to the 6th day of SC UFH therapy as in the FIDO regimen. 
Neither safety nor efficacy of patient outcomes were collected 
as the sample size was chosen only to validate the published 
dosing regimen.
Results
A total of 25 inpatients were recruited of whom 24 had acute 
DVT confirmed on Doppler ultrasound, and one had clinical 
evidence of PE and a strongly positive d-dimer result. The 
mean age of the patients was 37.6 years (SD 15.03); mean 
body weight 57.2 kg (SD 16.79) and 68% were female (Table I). 
Pulmonary tuberculosis was the most prevalent concomitant 
disease (64%). The mean loading and maintenance doses of 
UFH were 320 units/kg (SD 66.87) and 250 units/kg (SD 5.57) 
respectively. PTT was measured on a single blood sample 
obtained a mean of 6.0 hours (SD 0.37) after the morning 
dose and a mean of 3.48 days (SD 0.92) after starting SC 
UFH. Twelve (48%) of the 25 patients had a PTT within the 
therapeutic range, 8 (32%) patients were found to have a 
supratherapeutic PTT (patient value >2.5 times control value) 
and 5 (20%) had a sub-therapeutic PTT (patient value <1.5 
times control value). The mean PTT ratio (PTT patient/PTT 
control) was 2.44 (SD 1.40; 95% CI 1.89 to 2.99). The mean 
duration of heparin therapy was 8.5 days (SD 3.39).
Discussion
Baseline characteristics of patients in this study including 
gender, age and weight differed from the SC UFH treatment 
arm in FIDO (Table I). There were relatively more women than 
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men (68% versus 49% in FIDO) and the mean ages and weights 
were less (38 years v. 60 years and 57 kg v. 82 kg).
None of our patients had previous VTE, compared with 11% 
of patients in the SC UFH group in FIDO. Sixteen patients were 
diagnosed with DVT and concomitant tuberculosis but none in 
the SC UFH group in FIDO.
In FIDO, the PTT (therapeutic PTT: 60 - 85 seconds) was 
measured in 197 patients, a mean of 6.0 hours after the 
morning dose and a mean of 2.8 days after starting UFH.4 
Thirty-seven patients (19%) had a PTT within the therapeutic 
range, 121 (61%) were found to be supratherapeutic (>85 
seconds) and 39 (20%) sub-therapeutic (<60 seconds).4 A 
higher proportion of patients in our cohort appeared to 
have therapeutic values, while a lower proportion had 
supratherapeutic and a similar proportion sub-therapeutic 
values. The low sub-therapeutic ratio for 1 patient in our 
cohort may be attributed to 2 dose omissions prior to the blood 
samples taken for PTT monitoring.
Conclusion
In a small but real-world pragmatic study, the use of a 
weight-based dosing nomogram appeared feasible, and PTT 
results obtained were within the range achieved in a previous 
large trial comparing LMWH with fixed-dose, weight-based 
SC UFH. Our study provides preliminary support for the 
local generalisability of the FIDO dosing model, offering a 
promising alternative for the treatment of VTE in a resource-
constrained environment.
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Table I. Comparison between this study, FIDO and the dose validation study
                 Previous studies
    This study  Dose validation6   FIDO4
Baseline characteristics
Number of patients     25            20    355
Age, mean (SD) years     38 (15)            67    60 (17)
Weight, mean (SD) kg     57 (17)            78    82 (19)
Women (%)      68            60    49
PTT (Day 3)
Therapeutic, No. (%)     12 (48)            4 (20)   37 (19)
Supratherapeutic, No. (%)     8 (32)            12 (60)   121 (61)
Sub-therapeutic, No. (%)     5 (20)            4 (20)   39 (20)
Note: PTT was measured in 197 patients in the unfractionated heparin arm of FIDO.
